As a small molecule compound, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) can penetrate through the BBB in certain proportions, becoming an important theoretic mechanism for the treatment of NSCLC patients with BM. Here, EGFR is linked to non-small cell lung carcinoma.